Trials / Completed
CompletedNCT01342679
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Kanto CML Study Group · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dasatinib | 100mg QD |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2013-03-01
- Completion
- 2014-09-01
- First posted
- 2011-04-27
- Last updated
- 2015-09-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01342679. Inclusion in this directory is not an endorsement.